Article

Drug therapies for PBS/IC continue to evolve

With 183 drugs tied to painful bladder syndrome/interstitial cystitis and none hitting a home run, what should clinicians do?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
2 experts in this video
Fitting Oral ADT Options Into the Prostate Cancer Treatment Plans
2 experts in this video
The Current Landscape of ADT in Prostate Cancer
Daniel D. Joyce, MD, MS, answers a question during a Zoom video interview
Daniel D. Joyce, MD, MS, discusses the economics of trimodal therapy in MIBC
Sarah Razavi, MD, answers a question during a Zoom video interview
Sarah Razavi, MD, outlines strategies for mitigate surgeon discomfort during URS
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
Can ctDNA detect molecular residual disease in NMIBC?
Kevin T. McVary, MD, FACS, answers a question during a Zoom video interview
Expert discusses setting realistic expectations for Rezum for BPH
1 expert is featured in this series.
Considering Therapy De-Intensification: Balancing Adverse Effects and PSA Response
Nicolette G. Payne, MD, answers a question during a Zoom video interview
Nicolette G. Payne, MD, discusses risk factors for burnout among pediatric urologists
Andrea Pezzella, MD, URPS, FACOG, answers a question during a Zoom video interview
Sacral neuromodulation device empowers patients with greater UUI control
Howard Goldman, MD, on his experience with the Glean Urodynamics System
Howard Goldman, MD, on his experience with the Glean Urodynamics System
Related Content
FDA clears image-guided navigation platform for focal therapy in prostate cancer
July 23rd 2025

FDA clears image-guided navigation platform for focal therapy in prostate cancer

Hannah Clarke
The new advanced annotation workflow on the UroNav System is designed to work in tandem with DynaCAD Urology to support focal therapy planning.
Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD
July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD
Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.
When to report 50320 with 49187 for nephrectomy procedures
July 23rd 2025

When to report 50320 with 49187 for nephrectomy procedures

Jonathan Rubenstein, MD Mark Painter
"As always, we encourage you to communicate among all team members and pay attention to your documentation," write Jonathan Rubenstein, MD, and Mark Painter.
Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD
June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD
Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.
Water vapor therapy demonstrates superior outcomes vs pharmaceutical therapy for BPH
July 22nd 2025

Water vapor therapy demonstrates superior outcomes vs pharmaceutical therapy for BPH

Hannah Clarke
According to the authors, these data support Rezūm as an alternative first-line treatment option for patients at risk of BPH progression.
Prostate cancer, 3D illustration showing presence of tumor inside prostate gland which compresses urethra | Image Credit: © Dr_Microbe - stock.adobe.com
July 21st 2025

Darolutamide plus ADT approved in EU for mHSPC

Hannah Clarke
This approval enables the use of darolutamide plus ADT with or without chemotherapy.
© 2025 MJH Life Sciences

All rights reserved.